Physician profile
Kumar Venkatachalam
NPI 1154325421
$10,636.16
in general payments reported to CMS, 2019-2025
37 companies · $2,193 in 2025
The $2,193 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $844 · 2020: $362 · 2021: $1,317 · 2022: $1,836 · 2023: $2,504 · 2024: $1,580 · 2025: $2,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,190 · Education: $86.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,189.73 |
| Education | $86.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,982.15 | 2019-2025 | Skyrizi, Linzess, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,314.58 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,004.47 | 2019-2025 | Entyvio, Eohilia |
| Nestle Healthcare Nutrition INC. | $922.42 | 2020-2023 | |
| Janssen Biotech, INC. | $708.78 | 2019-2025 | Stelara, Tremfya, Simponi |
| Gilead Sciences, INC. | $461.75 | 2019-2025 | Epclusa |
| Ardelyx, INC. | $399.17 | 2022-2025 | Ibsrela |
| Celgene Corporation | $290.61 | 2022-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $277.37 | 2024-2025 | Voquezna |
| Vivus LLC | $267.97 | 2020-2025 | Pancreaze |
| Madrigal Pharmaceuticals | $244.21 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $232.04 | 2020-2025 | Linzess |
| Aimmune Therapeutics, INC. | $182.40 | 2024-2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $162.04 | 2020-2025 | Rebyota |
| Pfizer INC. | $138.42 | 2019-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $136.75 | 2019-2023 | Dificid, Zinplava |
| Genzyme Corporation | $126.91 | 2023-2025 | |
| Evoke Pharma, INC. | $94.60 | 2020-2025 | Gimoti |
| Lilly USA, LLC | $93.81 | 2024-2025 | Omvoh |
| Endogastric Solutions, INC | $70.84 | 2019 | |
| Celltrion USA INC. | $62.32 | 2025 | Vegzelma |
| Regeneron Healthcare Solutions, INC. | $61.70 | 2023 | Dupixent |
| Allergan, INC. | $55.09 | 2019-2020 | |
| Braintree Laboratories, INC. | $54.35 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $48.38 | 2025 | Iqirvo |
| Ucb, INC. | $39.91 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.74 | 2023-2024 | Cyltezo |
| Alfasigma USA, INC. | $26.22 | 2020 | |
| Recordati_rare_diseases_inc. | $24.97 | 2025 | Panhematin |
| Qol Medical, LLC | $18.63 | 2025 | Sucraid |
| Alnylam Pharmaceuticals INC. | $17.00 | 2023 | Givlaari |
| Sandoz INC. | $15.31 | 2024 | Hyrimoz |
| Redhill Biopharma INC. | $15.30 | 2020 | |
| Shield Therapeutics INC | $13.94 | 2024 | |
| Shire North American Group INC | $13.21 | 2019 | |
| Intercept Pharmaceuticals, INC. | $13.07 | 2019 | |
| Lucid Diagnostics INC. | $12.73 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kumar Venkatachalam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.